171 related articles for article (PubMed ID: 19383822)
1. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival.
Feng LY; Ou ZL; Wu FY; Shen ZZ; Shao ZM
Clin Cancer Res; 2009 May; 15(9):2962-70. PubMed ID: 19383822
[TBL] [Abstract][Full Text] [Related]
2. β-Arrestin recruitment and G protein signaling by the atypical human chemokine decoy receptor CCX-CKR.
Watts AO; Verkaar F; van der Lee MM; Timmerman CA; Kuijer M; van Offenbeek J; van Lith LH; Smit MJ; Leurs R; Zaman GJ; Vischer HF
J Biol Chem; 2013 Mar; 288(10):7169-81. PubMed ID: 23341447
[TBL] [Abstract][Full Text] [Related]
3. The atypical chemokine receptor CCX-CKR regulates metastasis of mammary carcinoma via an effect on EMT.
Harata-Lee Y; Turvey ME; Brazzatti JA; Gregor CE; Brown MP; Smyth MJ; Comerford I; McColl SR
Immunol Cell Biol; 2014 Nov; 92(10):815-24. PubMed ID: 25027038
[TBL] [Abstract][Full Text] [Related]
4. The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro.
Comerford I; Milasta S; Morrow V; Milligan G; Nibbs R
Eur J Immunol; 2006 Jul; 36(7):1904-16. PubMed ID: 16791897
[TBL] [Abstract][Full Text] [Related]
5. Endogenous expression of the atypical chemokine receptor CCX-CKR (CCRL1) gene in human embryonic kidney (HEK 293) cells.
Salimi P; Esmaeili A; Hashemi M; Behjati M
Mol Cell Biochem; 2016 Jan; 412(1-2):229-33. PubMed ID: 26699909
[TBL] [Abstract][Full Text] [Related]
6. The atypical chemokine receptor CCX-CKR scavenges homeostatic chemokines in circulation and tissues and suppresses Th17 responses.
Comerford I; Nibbs RJ; Litchfield W; Bunting M; Harata-Lee Y; Haylock-Jacobs S; Forrow S; Korner H; McColl SR
Blood; 2010 Nov; 116(20):4130-40. PubMed ID: 20562329
[TBL] [Abstract][Full Text] [Related]
7. Generation of a panel of monoclonal antibodies against atypical chemokine receptor CCX-CKR by DNA immunization.
Takatsuka S; Sekiguchi A; Tokunaga M; Fujimoto A; Chiba J
J Pharmacol Toxicol Methods; 2011; 63(3):250-7. PubMed ID: 21184834
[TBL] [Abstract][Full Text] [Related]
8. Expression of CCX CKR in pulmonary sarcoidosis.
Kriegova E; Tsyrulnyk A; Arakelyan A; Mrazek F; Ordeltova M; Petzmann S; Zatloukal J; Kolek V; du Bois RM; Popper H; Petrek M
Inflamm Res; 2006 Oct; 55(10):441-5. PubMed ID: 17109071
[TBL] [Abstract][Full Text] [Related]
9. CCX-CKR expression in colorectal cancer and patient survival.
Zhu Y; Tang W; Liu Y; Wang G; Liang Z; Cui L
Int J Biol Markers; 2014 Mar; 29(1):e40-8. PubMed ID: 24338720
[TBL] [Abstract][Full Text] [Related]
10. Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR.
Townson JR; Nibbs RJ
Eur J Immunol; 2002 May; 32(5):1230-41. PubMed ID: 11981810
[TBL] [Abstract][Full Text] [Related]
11. Transient expression of recombinant ACKR4 (CCRL1) gene, an atypical chemokine receptor in human embryonic kidney (HEK 293) cells.
Parsi B; Esmaeili A; Hashemi M; Behjati M
Mol Biol Rep; 2016 Jul; 43(7):583-9. PubMed ID: 27168154
[TBL] [Abstract][Full Text] [Related]
12. Chemokine decoy receptor d6 plays a negative role in human breast cancer.
Wu FY; Ou ZL; Feng LY; Luo JM; Wang LP; Shen ZZ; Shao ZM
Mol Cancer Res; 2008 Aug; 6(8):1276-88. PubMed ID: 18708360
[TBL] [Abstract][Full Text] [Related]
13. Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer.
Hou T; Liang D; Xu L; Huang X; Huang Y; Zhang Y
Gynecol Oncol; 2013 Jul; 130(1):181-7. PubMed ID: 23603371
[TBL] [Abstract][Full Text] [Related]
14. CCX-CKR deficiency alters thymic stroma impairing thymocyte development and promoting autoimmunity.
Bunting MD; Comerford I; Seach N; Hammett MV; Asquith DL; Körner H; Boyd RL; Nibbs RJ; McColl SR
Blood; 2013 Jan; 121(1):118-28. PubMed ID: 23152546
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CXCR3-mediated chemotaxis by the human chemokine receptor-like protein CCX-CKR.
Vinet J; van Zwam M; Dijkstra IM; Brouwer N; van Weering HR; Watts A; Meijer M; Fokkens MR; Kannan V; Verzijl D; Vischer HF; Smit MJ; Leurs R; Biber K; Boddeke HW
Br J Pharmacol; 2013 Mar; 168(6):1375-87. PubMed ID: 23121557
[TBL] [Abstract][Full Text] [Related]
16. Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.
Zeng XH; Ou ZL; Yu KD; Feng LY; Yin WJ; Li J; Shen ZZ; Shao ZM
Med Oncol; 2014 Sep; 31(9):145. PubMed ID: 25097078
[TBL] [Abstract][Full Text] [Related]
17. Regulation of breast cancer metastasis by atypical chemokine receptors.
Cheng X; Hung MC
Clin Cancer Res; 2009 May; 15(9):2951-3. PubMed ID: 19383808
[TBL] [Abstract][Full Text] [Related]
18. CRAM-A indicates IFN-γ-associated inflammatory response in breast cancer.
Sarmadi P; Tunali G; Esendagli-Yilmaz G; Yilmaz KB; Esendagli G
Mol Immunol; 2015 Dec; 68(2 Pt C):692-8. PubMed ID: 26563945
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential.
Wang J; Ou ZL; Hou YF; Luo JM; Shen ZZ; Ding J; Shao ZM
Oncogene; 2006 Nov; 25(54):7201-11. PubMed ID: 16785997
[TBL] [Abstract][Full Text] [Related]
20. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
Johnson EL; Singh R; Singh S; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW
World J Surg Oncol; 2010 Jul; 8():62. PubMed ID: 20649989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
